Medicare Enrolled
Dr. Brian Leberthon, M.D.
Hematology & Oncology · West Covina, CA
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Leberthon from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Leberthon?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Leberthon
Dr. Brian Leberthon is a hematology & oncology specialist in West Covina, CA, with 20 years of NPI registration. Based on federal Medicare data, Dr. Leberthon performed 8,787 Medicare services across 666 unique beneficiaries.
Between the years covered by Open Payments, Dr. Leberthon received a total of $38,273 from 100 pharmaceutical and/or device companies across 1637 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology & oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Leberthon is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 20 years in practice
▲ Top 29% volume in CA
$38,273 industry payments
Medicare Practice Summary
Medicare Utilization ↗8,787
Medicare services
Top 29% in CA for hematology & oncology
666
Unique beneficiaries
$38
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~439 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Denosumab injection (Prolia/Xgeva) | 4,200 | $15 | $26 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
1,136 | $152 | $260 |
| Prolonged office E/M service, first 15 minutes This code is used for additional time spent by a physician beyond the maximum required time of a primary office or outpatient evaluation and management service. It is billed in 15-minute increments based on total time spent on the date of the primary service. |
750 | $28 | $70 |
| Additional hour of intravenous hydration This code represents each additional hour of intravenous fluid administration beyond the initial hour. It is used to bill for extended hydration therapy. |
552 | $11 | $43 |
| Additional hour of intravenous infusion This code represents each additional hour of intravenous infusion beyond the initial hour for therapy, prevention, or diagnosis. |
495 | $19 | $51 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
320 | $27 | $114 |
| Normal saline infusion, 250 cc Administration of 250 cubic centimeters of normal saline solution into a vein. This procedure involves the intravenous delivery of a sterile saltwater fluid. |
315 | $0 | $20 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
223 | $123 | $245 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
218 | $12 | $34 |
| Diphenhydramine injection, up to 50 mg An injection of diphenhydramine hydrochloride, an antihistamine medication, administered in a dose of up to 50 milligrams. |
207 | $1 | $24 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
186 | $59 | $125 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
116 | $26 | $60 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
33 | $110 | $190 |
| Smoking cessation counseling, 4-10 minutes A brief counseling session focused on helping patients quit smoking and tobacco use. The provider spends 4 to 10 minutes discussing strategies and support for cessation. |
24 | $16 | $16 |
| New patient office visit, complex (60-74 min) | 12 | $193 | $300 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
17.5% high complexity
54.0% medium
28.5% routine
Industry Payment Transparency
Open Payments through 2024 ↗$38,273
Total received (2018-2024)
Avg $5,468/year across 7 years
Top 14% in CA for hematology & oncology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
100
Companies
1,637
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$32,879 (85.9%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$4,037 (10.5%)
Other
Charitable contributions, space rental, and other categories
$816 (2.1%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$541 (1.4%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$6,011
2023
$6,206
2022
$5,706
2021
$4,876
2020
$3,717
2019
$4,277
2018
$7,481
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
AstraZeneca Pharmaceuticals LP
$1,113
Incyte Corporation
$468
Daiichi Sankyo Inc.
$402
PFIZER INC.
$327
Novartis Pharmaceuticals Corporation
$308
Janssen Biotech, Inc.
$289
Alexion Pharmaceuticals, Inc.
$283
Acrotech Biopharma Inc.
$271
Merck Sharp & Dohme LLC
$194
Gilead Sciences, Inc.
$185
JAZZ PHARMACEUTICALS INC.
$172
ABBVIE INC.
$133
E.R. Squibb & Sons, L.L.C.
$121
GENZYME CORPORATION
$117
Amgen Inc.
$116
GlaxoSmithKline, LLC.
$111
EMD Serono, Inc.
$107
Agios Pharmaceuticals, Inc.
$102
Celgene Corporation
$100
PharmaEssentia USA Corporation
$97
Takeda Pharmaceuticals U.S.A., Inc.
$81
Karyopharm Therapeutics Inc.
$78
PUMA BIOTECHNOLOGY, INC.
$68
Coherus Biosciences Inc.
$65
Spectrum Pharmaceuticals Inc.
$60
SOBI, INC
$58
BeiGene USA, Inc.
$52
Otsuka America Pharmaceutical, Inc.
$50
Ipsen Biopharmaceuticals, Inc
$49
Boehringer Ingelheim Pharmaceuticals, Inc.
$48
Janssen Pharmaceuticals, Inc
$44
TAIHO ONCOLOGY, INC.
$34
Aveo Pharmaceuticals, Inc.
$32
Legend Biotech USA Inc.
$28
ARRAY BIOPHARMA INC
$27
Stemline Therapeutics Inc.
$27
Lilly USA, LLC
$24
Kyowa Kirin, Inc.
$22
Pharmacosmos Therapeutics Inc.
$21
Astellas Pharma US Inc
$21
Novocure Inc.
$20
ImmunoGen, Inc.
$20
Eisai Inc.
$18
Genentech USA, Inc.
$18
Mirati Therapeutics, Inc.
$15
Menarini Silicon Biosystems, Inc.
$14
Top 3 companies account for 33.0% of 2024 payments
All-time payments by company (2018-2024) ›
AstraZeneca Pharmaceuticals LP
$6,775
Novartis Pharmaceuticals Corporation
$2,595
E.R. Squibb & Sons, L.L.C.
$2,436
Incyte Corporation
$1,907
Celgene Corporation
$1,770
Amgen Inc.
$1,504
GENZYME CORPORATION
$1,331
PFIZER INC.
$1,266
Genentech USA, Inc.
$1,136
Bayer HealthCare Pharmaceuticals Inc.
$1,124
Alexion Pharmaceuticals, Inc.
$1,017
Puma Biotechnology, Inc.
$982
Daiichi Sankyo Inc.
$874
Gilead Sciences, Inc.
$805
Janssen Biotech, Inc.
$723
Takeda Pharmaceuticals U.S.A., Inc.
$719
Merck Sharp & Dohme Corporation
$611
Karyopharm Therapeutics Inc.
$540
Pharmacyclics LLC, An AbbVie Company
$497
Merck Sharp & Dohme LLC
$468
PUMA BIOTECHNOLOGY, INC.
$433
Seagen Inc.
$430
Lilly USA, LLC
$427
Foundation Medicine, Inc.
$424
GlaxoSmithKline, LLC.
$345
Acrotech Biopharma Inc.
$339
EMD Serono, Inc.
$334
JAZZ PHARMACEUTICALS INC.
$322
TerSera Therapeutics LLC
$268
Astellas Pharma US Inc
$232
INSYS Therapeutics Inc
$210
ARRAY BIOPHARMA INC
$208
ABBVIE INC.
$206
Taiho Oncology, Inc.
$180
Agios Pharmaceuticals, Inc.
$179
Exelixis Inc.
$177
TESARO, Inc.
$173
PharmaEssentia USA Corporation
$169
NOVARTIS PHARMACEUTICALS CORPORATION
$167
Jazz Pharmaceuticals Inc.
$166
Spectrum Pharmaceuticals Inc.
$133
Dendreon Pharmaceuticals LLC
$132
Eisai Inc.
$132
Stemline Therapeutics Inc.
$126
Teva Pharmaceuticals USA, Inc.
$121
Otsuka America Pharmaceutical, Inc.
$120
BeiGene USA, Inc.
$106
Janssen Scientific Affairs, LLC
$102
Kyowa Kirin, Inc.
$102
Pharmacyclics LLC, an AbbVie Company
$101
Mirati Therapeutics, Inc.
$99
Immunocore Limited
$97
Rigel Pharmaceuticals, Inc.
$92
Verastem, Inc.
$91
TAIHO ONCOLOGY, INC.
$88
Boehringer Ingelheim Pharmaceuticals, Inc.
$88
Ipsen Biopharmaceuticals, Inc
$87
Regeneron Healthcare Solutions, Inc.
$85
Clovis Oncology, Inc.
$84
MEDIVATION FIELD SOLUTIONS LLC
$84
Helsinn Therapeutics (U.S.), Inc.
$84
Coherus Biosciences Inc.
$83
Partner Therapeutics, Inc.
$82
Novocure Inc.
$81
AVEO Pharmaceuticals, Inc.
$75
Myovant Sciences Inc.
$75
EISAI INC.
$74
ImmunoGen, Inc.
$70
Janssen Pharmaceuticals, Inc
$67
EUSA Pharma (US) LLC
$66
Secura Bio, Inc.
$65
Epizyme, Inc.,
$64
Sumitomo Pharma America, Inc.
$62
Alnylam Pharmaceuticals Inc.
$59
SOBI, INC
$58
Kite Pharma, Inc.
$47
Acrotech Biopharma LLC
$46
Bayer Healthcare Pharmaceuticals Inc.
$42
Sobi, Inc
$40
Dova Pharmaceuticals
$40
Mylan Institutional Inc.
$39
Deciphera Pharmaceuticals Inc.
$36
SANOFI-AVENTIS U.S. LLC
$36
Aveo Pharmaceuticals, Inc.
$32
AbbVie, Inc.
$32
Genmab U.S., Inc.
$30
Legend Biotech USA Inc.
$28
ADC Therapeutics America, Inc.
$24
Adaptive Biotechnologies Corporation
$23
Pharmacosmos Therapeutics Inc.
$21
Global Blood Therapeutics, Inc.
$20
West Therapeutics Development, LLC
$20
MorphoSys, US Inc.
$18
GE HEALTHCARE
$16
GE HealthCare
$15
Allergan Inc.
$15
Aurobindo Pharma USA, Inc.
$14
Shire North American Group Inc
$14
Menarini Silicon Biosystems, Inc.
$14
Immunomedics, Inc.
$11
Top 3 companies account for 30.8% of all-time payments
Associated products mentioned in payments ›
ABECMA · ADCETRIS · AFINITOR · AKYNZEO · ALOXI · ALUNBRIG · Alecensa · Aliqopa · Andexxa · Avastin · BAVENCIO · BELEODAQ · BENDEKA · BESREMI · BLENREP · BOSULIF · BRAFTOVI · BRUKINSA · Balversa · Bavencio · CABLIVI · CABOMETYX · CALQUENCE · CERDELGA · COSELA · CYRAMZA · Cabometyx · Cellsearch · Copiktra · DALVANCE · DARZALEX · DOPTELET · Doptelet · ELAHERE · ELIQUIS · ELITEK · ELZONRIS · EMPLICITI · ENHERTU · EPKINLY · ERBITUX · ERLEADA · EVENITY · Elahere · Enhertu · Epkinly · Erleada · FARESTON · FASLODEX · FOLOTYN · FOTIVDA · FOUNDATIONONE · FOUNDATIONONE CDX · FRUZAQLA · Fabhalta · Farydak · Folotyn · GAMIFANT · GILOTRIF · Halaven · IBRANCE · ICLUSIG · IMBRUVICA · IMFINZI · INJECTAFER · INLYTA · INQOVI · Idhifa · Imbruvica · JADENU · JAKAFI · JEMPERLI · JEVTANA · JYNARQUE · KANJINTI · KEYTRUDA · KIMMTRAK · KISQALI · KRAZATI · Kadcyla · Kyprolis · LEMTRADA · LEUKINE · LIBTAYO · LONSURF · LUMAKRAS · LUTATHERA · LYNPARZA · Lenvima · Leukine · Lonsurf · MEKINIST · MONJUVI · MYLOTARG · NERLYNX · NINLARO · Nerlynx · Neulasta · Nplate · Nubeqa · OCREVUS · OJJAARA · ONPATTRO · ONUREG · OPDIVO · OPDUALAG · ORGOVYX · OXBRYTA · Ogivri · Onivyde · Optune · Orserdu · PADCEV · PEMAZYRE · PIQRAY · PROMACTA · PROVENGE · PYRUKYND · Padcev · Perjeta · Pomalyst · Poteligeo · Prolia · QINLOCK · Quzyttir · REBLOZYL · ROLVEDON · RYBREVANT · RYDAPT · Revlimid · Rezlidhia · Rituxan Hycela · Rubraca · SANCUSO · SANDOSTATIN · SARCLISA · SCEMBLIX · SOLIRIS · SOMATULINE DEPOT · SPRYCEL · SUTENT · SYNAGIS · SYNDROS · Stivarga · Subsys · Sylvant · TABRECTA · TAGRISSO · TASIGNA · TAZVERIK · TECENTRIQ · TIBSOVO · TIVDAK · TUKYSA · Tavalisse · Trodelvy · ULTOMIRIS · Udenyca · Ultomiris · VARUBI · VELCADE · VENCLEXTA · VERZENIO · VOTRIENT · VPRIV · VYXEOS · Vanflyta · Venclexta · XALKORI · XARELTO · XERMELO · XGEVA · XPOVIO · XTANDI · Xermelo · Yescarta · ZEJULA · ZEPZELCA · ZOLADEX · clonoSEQ
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (86%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Geographic Context
Hematology & oncology specialists within 10 mi
300
Per 100K population
3.0
County median income
$87,760
Nearest hospital
KAISER FOUNDATION HOSPITAL - BALDWIN PARK
2.8 mi
2.8 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Leberthon is a mixed practice specialist, with above-average Medicare volume (top 29% in CA), with low-engagement industry engagement in the top 14% of CA peers, with 20 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Leberthon experienced with denosumab injection (prolia/xgeva)?
Based on Medicare claims data, Dr. Leberthon performed 4,200 denosumab injection (prolia/xgeva) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Leberthon receive payments from pharmaceutical companies?
Yes. Dr. Leberthon received a total of $38,273 from 100 companies across 1,637 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Leberthon's costs compare to other hematology & oncology specialists in West Covina?
Dr. Leberthon's average Medicare payment per service is $38. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Leberthon) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Hematology & Oncology Specialists in West Covina
Browse hematology & oncology specialists in West Covina ranked by procedure volume and transparency data.
Highest volume
Top Hematology & Oncology Specialists in CA
Hematology & oncology specialists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematology & Oncology Specialists in CA
Which CA hematology & oncology specialists receive the most from drug and device companies.
By company
AstraZeneca Pharmaceuticals LP Payments to Doctors
See all physicians who received payments from AstraZeneca Pharmaceuticals LP.
By company
Novartis Pharmaceuticals Corporation Payments to Doctors
See all physicians who received payments from Novartis Pharmaceuticals Corporation.
By company
E.R. Squibb & Sons, L.L.C. Payments to Doctors
See all physicians who received payments from E.R. Squibb & Sons, L.L.C.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology